Perrigo Company Securities Class Action Notice, Compensation Deadline January 16, 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: PRnewswire
- Class Action Notice: Rosen Law Firm reminds investors who purchased Perrigo securities between February 27, 2023, and November 4, 2025, that the deadline to apply as lead plaintiff is January 16, 2026, allowing for potential compensation without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that Perrigo failed to disclose significant underinvestment and manufacturing deficiencies in its acquired infant formula business from Nestlé, leading to overstated financial results and subsequent investor losses when the truth emerged.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions, having recovered over $438 million for investors in 2019 alone, and was ranked first in 2017 for the number of securities class action settlements, showcasing its expertise in this field.
- Investor Guidance: Investors are advised to carefully select qualified counsel with a proven track record, avoiding firms that merely act as intermediaries, to ensure effective legal representation in the class action process.
Analyst Views on PRGO
Wall Street analysts forecast PRGO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PRGO is 27.50 USD with a low forecast of 23.00 USD and a high forecast of 32.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 15.170
Low
23.00
Averages
27.50
High
32.00
Current: 15.170
Low
23.00
Averages
27.50
High
32.00
About PRGO
Perrigo Company plc is a provider of over the counter (OTC) health and wellness solutions that are designed to enhance individual well-being. Its segments include Consumer Self-Care Americas (CSCA) and Consumer Self-Care International (CSCI). The CSCA segment comprises of its consumer self-care business in the United States and Canada. It primarily provides its customers self-care products that are sold and marketed under the customer's own brands and/or exclusive brands. The CSCI segment comprises of its consumer self-care business outside of the United States and Canada, primarily in Europe and Australia. These products are developed, manufactured, marketed, and distributed by the Company. Its product categories include Upper Respiratory, Pain and Sleep-Aids, Skincare and Personal Hygiene, Digestive Health, and Nutrition. Its primary branded products are sold under brand names Compeed, Dr. Fresh, Firefly, Good Sense, Mederma, Nasonex, Solpadeine, Coldrex, and Physiomer, among others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
